Read by QxMD icon Read


shared collection
8 papers 100 to 500 followers
Richard Holland, William Tillett, Eleanor Korendowych, Charlotte Cavill, Nicola Waldron, Melanie Brooke, Neil J McHugh
OBJECTIVES: The Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire is a recently developed patient-reported outcome measure (PROM) of disease impact in psoriatic arthritis (PsA). We set out to assess the validity in an independent cohort of patients, estimate the minimally important difference for improvement and explore the potential of individual components of the PsAID in clinical practice. METHODS: Data were collected prospectively for a single-centre cohort of patients with PsA...
March 2018: Annals of the Rheumatic Diseases
E Peleva, L S Exton, K Kelley, C E Kleyn, K J Mason, C H Smith
BACKGROUND: Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms. OBJECTIVES: To investigate the risk of cancer in patients with psoriasis treated with biological therapy. METHODS: We searched MEDLINE, Embase, and the Cochrane Library (up to August 2016) for randomized controlled trials, prospective cohort studies and systematic reviews that reported cancer incidence in people exposed to biological therapy for psoriasis compared with a control population...
January 2018: British Journal of Dermatology
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn, Mittie K Doyle
BACKGROUND: Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody ustekinumab is an efficacious treatment for moderate-to-severe plaque psoriasis. We did a randomised, placebo-controlled, phase 3 trial to assess the safety and efficacy of ustekinumab in patients with active psoriatic arthritis. METHODS: In this phase 3, multicentre, double-blind, placebo-controlled trial at 104 sites in Europe, North America, and Asia-Pacific, adults with active psoriatic arthritis (≥5 tender and ≥5 swollen joints, C-reactive protein ≥3·0 mg/L) were randomly assigned (1:1:1, by dynamic central randomisation based on an algorithm implemented by an interactive voice-web response system) to 45 mg ustekinumab, 90 mg ustekinumab, or placebo at week 0, week 4, and every 12 weeks thereafter...
August 31, 2013: Lancet
Brittany G Craiglow, Brett A King
No abstract text is available yet for this article.
December 2014: Journal of Investigative Dermatology
Kim Papp, Craig Leonardi, Alan Menter, Elizabeth H Z Thompson, Cassandra E Milmont, Greg Kricorian, Ajay Nirula, Paul Klekotka
BACKGROUND: Brodalumab (anti-interleukin-17-receptor antibody) was effective in treating moderate to severe psoriasis in a 12-week, dose-ranging, placebo-controlled trial. OBJECTIVE: We sought to evaluate efficacy and safety of long-term brodalumab treatment. METHODS: In this interim analysis at week 120 of an open-label extension study, patients received brodalumab 210 mg every 2 weeks. Protocol amendments reduced the dose (140 mg) in patients weighing 100 kg or less and subsequently increased the dose (210 mg) in patients with inadequate responses...
December 2014: Journal of the American Academy of Dermatology
Bingshan Li, Lam C Tsoi, William R Swindell, Johann E Gudjonsson, Trilokraj Tejasvi, Andrew Johnston, Jun Ding, Philip E Stuart, Xianying Xing, James J Kochkodan, John J Voorhees, Hyun M Kang, Rajan P Nair, Goncalo R Abecasis, James T Elder
To increase our understanding of psoriasis, we used high-throughput complementary DNA sequencing (RNA-seq) to assay the transcriptomes of lesional psoriatic and normal skin. We sequenced polyadenylated RNA-derived complementary DNAs from 92 psoriatic and 82 normal punch biopsies, generating an average of ∼38 million single-end 80-bp reads per sample. Comparison of 42 samples examined by both RNA-seq and microarray revealed marked differences in sensitivity, with transcripts identified only by RNA-seq having much lower expression than those also identified by microarray...
July 2014: Journal of Investigative Dermatology
April W Armstrong
OBJECTIVE: To assess whether patients with psoriasis treated with tumor necrosis factor (TNF) inhibitors have a decreased risk of myocardial infarction (MI) compared with those not treated with TNF inhibitors. DESIGN: Retrospective cohort study. SETTING: Kaiser Permanente Southern California health plan. PATIENTS: Patients with at least 3 International Classification of Diseases, Ninth Revision, Clinical Modification, codes for psoriasis (696...
May 15, 2013: JAMA: the Journal of the American Medical Association
Jose Luis Sanchez-Carazo, Jose Luis López-Estebaranz, Cristina Guisado
Psoriasis is a common, chronic inflammatory immunologically mediated disease of the skin, showing a high prevalence of associated comorbidities, and strongly affecting patients' health-related quality of life (HR-QOL), with profound impact on the psychological aspect. We aimed to establish the correlation between HR-QOL and the associated comorbidities in patients with moderate to severe psoriasis in Spain. A cross-sectional, observational, epidemiological study was conducted at 68 dermatology-based centers across Spain...
August 2014: Journal of Dermatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"